Abstract
The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) was set up to investigate the reproducibility and prognostic value of routine assessments of morphometric parameters [mean nuclear area (MNA), mitotic activity index (MAI), and multivariate prognostic index (MPI)] and cytometric features (DNA ploidy and index, % S-phase cells, as well as other cell cycle data) in comparison with classical prognostic parameters and steroid receptors. Thirty-four hospitals in six geographic regions participated. In 1988-1989, 3427 patients entered the study and morphometric assessments were made. An interim (1993) survival analysis indicated that MAI, MNA, and MPI are the strongest predictors of outcome. A Phase III randomized prospective multi-center trial [Premenopausal Morphometric Intervention Study (PREMIS)] using these endpoints was initiated in Europe to evaluate adjuvant [cyclophosphamide, methotrexate and 5-fluorouracil (CMF)] chemotherapy versus observation in morphometrically high risk (i.e., MAI > 10), premenopausal, lymph node negative (LN-) breast cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 220-5 |
| Number of pages | 6 |
| Journal | Journal of cellular biochemistry. Supplement |
| Volume | 17G |
| Publication status | Published - 1993 |
Keywords
- Breast Neoplasms
- Cell Differentiation
- Clinical Trials as Topic
- Female
- Humans
- Mitosis
- Mitotic Index
- Netherlands
- Prognosis
- Randomized Controlled Trials as Topic
- Reproducibility of Results
- Severity of Illness Index